BTIG analyst Kaveri Pohlman reiterated a Buy rating on Oncternal Therapeutics (ONCT – Research Report) on June 4 and set a price target of $5.00. The company's shares closed last Friday at $1.23, close to its 52-week low of $0.69. According to TipRanks.com, Pohlman is ranked 0 out of 5 stars with an average return of -28.5% and a 10.6% success rate. Pohlman covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Mersana Therapeutics, and Gritstone Oncology. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oncternal Therapeutics with a $8.70 average price target, representing a 517.0% upside.
https://www.tipranks.com/news/blurbs/oncternal-therapeutics-onct-gets-a-buy-rating-from-btig?utm_source=advfn.com&utm_medium=referral
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Jul 2022 até Ago 2022 Click aqui para mais gráficos Oncternal Therapeutics.
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Ago 2021 até Ago 2022 Click aqui para mais gráficos Oncternal Therapeutics.